YMTracker DRIPCalc v2 Launch sale

NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

ADMA | NASDAQ

$9.96 -$0.16 | -1.58%

SIGNAL:

Signal available — unlock to view

|2026-09-23 |F&G 55 |RSI 60.5

Add to favoritesFavorite

Company Overview:

Market Cap: $2.23B

Trailing PE: 14.2x

FWD PE *: 12.3x

Payout Ratio (TTM): —

52-Week Range: $7.21 - $20.46

* Forward PE is based on street estimates.

10 Year ADMA Performance Metrics:

Total Return (with DRIP): 37.6% (3.24% CAGR)

Total Return (no DRIP): 37.6% (3.24% CAGR)

Share Price: 37.6% (3.24% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $13,757

Total Return $ (with DRIP): $3,757

ADMA Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

ADMA Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

ADMA Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

ADMA - Revenue

ADMA Revenue CAGR:1Y: 1.98%2Y: 7.73%5Y: 47.48%10Y: 49.23%

ADMA - Earnings Per Share (EPS)

ADMA EPS CAGR:1Y: 14.29%2Y: 10.94%5Y: 0.00%10Y: 0.00%

ADMA - Net Income

🔓 See the full chart40% off right now · 7-day free trial

ADMA Net Income CAGR:1Y: 10.53%2Y: 8.61%5Y: 0.00%10Y: 0.00%

ADMA - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

ADMA EBITDA CAGR:1Y: 30.22%2Y: 17.23%5Y: 0.00%10Y: 0.00%

ADMA - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

ADMA Free Cash Flow CAGR:1Y: 45.77%2Y: -20.60%5Y: 0.00%10Y: 0.00%

ADMA - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

ADMA Free Cash Flow / Share CAGR:1Y: 54.23%2Y: -19.88%5Y: 0.00%10Y: 0.00%

ADMA - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

ADMA Operating Income CAGR:1Y: 22.54%2Y: 15.67%5Y: 0.00%10Y: 0.00%

ADMA - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

ADMA Gross Profit CAGR:1Y: 28.34%2Y: 22.70%5Y: 0.00%10Y: 0.00%

ADMA - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

ADMA Shares Outstanding CAGR:1Y: -7.35%2Y: -2.47%5Y: 12.57%10Y: 34.24%

ADMA - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

ADMA Share Buybacks CAGR:1Y: 0.00%2Y: 501.27%5Y: 0.00%10Y: 0.00%

ADMA - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ADMA Stock-Based Comp CAGR:1Y: 23.61%2Y: 46.39%5Y: 50.10%10Y: 34.75%

ADMA - Expenses

🔓 See the full chart40% off right now · 7-day free trial

ADMA Expenses CAGR:1Y: -6.85%2Y: -2.33%5Y: -12.80%10Y: 49.45%

ADMA - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

ADMA - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ADMA - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

ADMA - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ADMA - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ADMA - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

ADMA - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

ADMA Revenue CAGR:1Y: 1.98%2Y: 7.73%5Y: 47.48%10Y: 49.23%

ADMA - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

ADMA Revenue CAGR:1Y: 1.98%2Y: 7.73%5Y: 47.48%10Y: 49.23%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

ADMA - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ADMA Actual Revenue CAGR:1Y: 1.98%2Y: 7.73%5Y: 47.48%10Y: 49.23%

ADMA - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ADMA Actual EPS CAGR:1Y: 14.29%2Y: 10.94%5Y: 0.00%10Y: 0.00%

ADMA - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ADMA Actual Net Income CAGR:1Y: 10.53%2Y: 8.61%5Y: 0.00%10Y: 0.00%

ADMA - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ADMA Actual EBITDA CAGR:1Y: 30.22%2Y: 17.23%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

ADMA - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ADMA Net Profit Margin CAGR:1Y: 8.38%2Y: 0.82%5Y: 0.00%10Y: 0.00%

ADMA - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ADMA Gross Profit Margin CAGR:1Y: 25.86%2Y: 13.89%5Y: 0.00%10Y: 5.44%

ADMA - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

ADMA Price to Earnings CAGR:1Y: -62.15%2Y: -23.32%5Y: 0.00%10Y: 0.00%

ADMA - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

ADMA Price To Sales Ratio CAGR:1Y: -57.40%2Y: -21.69%5Y: 6.31%10Y: -7.01%

ADMA - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

ADMA Return on Capital Employed CAGR:1Y: -2.64%2Y: -14.53%5Y: 0.00%10Y: 0.00%

ADMA - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

ADMA Return on Invested Capital CAGR:1Y: -14.60%2Y: -21.63%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for ADMA

Based on past 10-year performance, here are ADMA growth metrics:

Share price CAGR of +3.13%
Dividend CAGR of +0%

Using ADMA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	ADMA (DRIP)	ADMA - No DRIP
Current Price	$9.96	$9.96
Start Shares	1,004.02	1,004.02
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	1,004.02	1,004.02
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$9.96	$9.96
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - ADMA

NOTE: Above numbers are our estimate based on ADMA's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

ADMA Biologics, Inc. (ADMA) had its IPO on 2013-10-17, and is traded on NASDAQ stock exchange.

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

ADMA website: https://www.admabiologics.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — ADMA

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $9.96

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own ADMA? See every dividend it's paid you

Add your ADMA shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every ADMA dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

Add ADMA free →

Free plan · up to 5 holdings